Aeterna Zentris (NASDAQ:), an oncology- and endocrine drug company, has seen significant advances in unmet medical requirements. However, the commercialization of its diagnostic and therapeutic products is still in clinical and preclinical stages. Additionally, given the concerns related to the company’s Nasdaq listing compliance notice and its shaky financials, is it worth betting on the stock at the current price level? Let’s find out.Specialty biopharmaceutical company Aeterna Zentaris Inc. (AEZS) is focused on developing and commercializing therapeutics and diagnostic tests. The company’s lead product Macrilen has potential uses in both endocrinology and oncology indications. In addition, it has a license agreement with Julius-Maximilians-University Wuerzburg for developing an oral prophylactic bacterial vaccine against COVID-19 disease.

AEZS’ shares have surged 44.2% year-to-date, fueled by the company’s efforts to advance the development of its AIM Biologicals pre-clinical program. However, the stock plunged 15.7% in the past month and 30% over three months. This is due to investor concern over AEZS’ non-compliance of the Nasdaq listing requirements and concerns about possible delisting.

Closing yesterday’s session at $0.61, the stock is trading 83.1% below its 52-week high of $3.62. The company’s underwhelming financials could cause its shares to witness a pullback soon. Its COVID-19 potential oral active vaccine remains in preclinical planning. Therefore, it is not clear what the future revenue-generating opportunities for the drug are.

Continue reading on StockNews